• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Seroquel (quetiapine fumarate)

Audience: Neuropsychiatric healthcare professionals and Pharmacists

AstraZeneca received reports of medication errors involving confusion between its atypical antipsychotic Seroquel (quetiapine fumarate), indicated for the treatment of schizophrenia, and Serzone (nefazodone hydrochloride), a product of Bristol-Myers Squibb, indicated for the treatment of depression. In addition to the similarity in names between Seroquel and Serzone, the overlapping strengths (100 mg and 200 mg), the dosage forms (tablets), the dosing interval (BID), and the fact that these two products were stocked close together in pharmacies were also critical in causing these errors.

[May 20, 2002 - Letter - AstraZeneca]